PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (the “Company”) (NASDAQ:PDGI), a leading provider of global drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today reported a net loss from continuing operations for its second quarter ended June 30, 2007 of $4.6 million, or $0.25 per diluted share, compared to a net loss of $3.7 million, or $0.21 per diluted share, in the second quarter 2006.
